Swiss National Bank Boosts Stock Position in Sotera Health (NASDAQ:SHC)

Swiss National Bank raised its stake in Sotera Health (NASDAQ:SHC) by 10.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 306,400 shares of the company’s stock after purchasing an additional 30,100 shares during the quarter. Swiss National Bank owned 0.11% of Sotera Health worth $4,192,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of SHC. Wealth Enhancement Advisory Services LLC lifted its position in Sotera Health by 2.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 51,940 shares of the company’s stock valued at $711,000 after purchasing an additional 1,047 shares during the period. GAMMA Investing LLC raised its stake in shares of Sotera Health by 37.5% during the 4th quarter. GAMMA Investing LLC now owns 4,109 shares of the company’s stock worth $56,000 after buying an additional 1,121 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Sotera Health by 164.3% in the 4th quarter. Blue Trust Inc. now owns 1,834 shares of the company’s stock valued at $25,000 after buying an additional 1,140 shares during the period. True Wealth Design LLC purchased a new stake in shares of Sotera Health in the third quarter valued at approximately $32,000. Finally, Amalgamated Bank boosted its stake in shares of Sotera Health by 3.4% in the fourth quarter. Amalgamated Bank now owns 72,715 shares of the company’s stock valued at $995,000 after buying an additional 2,368 shares in the last quarter. Institutional investors and hedge funds own 91.03% of the company’s stock.

Analysts Set New Price Targets

SHC has been the subject of a number of recent analyst reports. Barclays reduced their target price on Sotera Health from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, February 28th. The Goldman Sachs Group started coverage on shares of Sotera Health in a report on Friday, December 6th. They issued a “neutral” rating and a $14.00 price target for the company. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Sotera Health Stock Down 2.3 %

Sotera Health stock opened at $11.93 on Wednesday. The firm has a market capitalization of $3.38 billion, a price-to-earnings ratio of 47.72 and a beta of 1.92. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. Sotera Health has a fifty-two week low of $10.71 and a fifty-two week high of $17.08. The stock’s fifty day moving average is $12.90 and its two-hundred day moving average is $14.08.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.